Please assess the completion status of the following clinical trial:

Trial Title: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Documented evidence of hormone receptor-positive human epidermal growth factor receptor 2 negative (HER2-negative) (hormonal receptor-positive (HR+)/HER2-) metastatic breast cancer (MBC) confirmed.~* Refractory to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for metastatic disease:~  * At least 1 taxane in any setting.~ * At least 1 prior anticancer hormonal treatment in any setting.~ * At least 1 cyclin-dependent kinase inhibitor 4/6 in any setting.~* Eligible for one of the chemotherapy options listed in the TPC arm.~* Documented disease progression after the most recent therapy.~* Adequate bone marrow function (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1,500 per mm\^3, platelets ≥ 100,000 per mm\^3).~* Adequate renal function: calculated creatinine clearance ≥ 30 mL/minute according to the Cockcroft and Gault formula .~* Adequate liver function (bilirubin ≤ 1.5 institutional upper limit of normal (IULN), or ≤ 3 IULN for individuals with documented Gilbert's syndrome, aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x IULN (in the case of liver metastases ≤ 5.0 x IULN)).~* Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta human chorionic gonadotropin (ß-hCG)).~Key Exclusion Criteria:~* Previous treatment with topoisomerase 1 Inhibitors as a free form or as other formulations.~* History of significant cardiovascular disease or clinically significant electrocardiogram (ECG) abnormality.~* Active serious infection requiring antibiotics.~* Any medical or other condition which, in the opinion of the Investigator, causes the individual to be medically unfit to receive sacituzumab govitecan or unsuitable for any reason.~* Locally advanced MBC (stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sacituzumab Govitecan-hziy (Type: EXPERIMENTAL): Participants will receive sacituzumab govitecan-hziy 10 mg/kg via intravenous (IV) injection administered on Day 1 and Day 8 of a 21-day cycle.
- Treatment of Physician's Choice (TPC) (Type: ACTIVE_COMPARATOR): Participants will receive TPC determined prior to randomization from one of the following single-agent treatment:~Dosing per National Comprehensive Cancer Network (NCCN) guidelines (with dose modifications for if toxic)~* Eribulin: 1.4 mg/m\^2 for North American sites, 1.23 mg/m\^2 for European sites) via IV on Days 1 and 8 of a 21-day cycle~* Capecitabine: 1000-1250 mg/m\^2 orally twice daily for 2 weeks followed by a 1-week rest period given as a 21-day cycle~* Gemcitabine: 800-1200 mg/m\^2 via IV on Days 1, 8, and 15 of each 28-day cycle or per institution~* Vinorelbine: 25 mg/m\^2 via IV on Day 1 weekly cycle per institution

Based on this trial design, predict the completion outcome and termination type (if applicable).